jun 5, 2019: 1:45 p.m. - 2:45 p.m.
109AB, Level 100
As larger biotech and pharmaceutical companies seek to expand or strengthen their product portfolios, smaller companies continue to attract merger and acquisition (M&A) interest. This session will recap M&A related risks and will identify which can be mitigated and transferred through strong contractual controls, successor liability, representations and warranties insurance. Panelists will include representatives from life sciences companies, representatives with real-world experience on the buyer and seller side as well as an M&A attorney and insurance underwriter.